Cargando…
The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson’s disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883364/ https://www.ncbi.nlm.nih.gov/pubmed/31819763 http://dx.doi.org/10.1177/1756286419888601 |
_version_ | 1783474366592319488 |
---|---|
author | Morgante, Francesca Bavikatte, Ganesh Anwar, Fahim Mohamed, Biju |
author_facet | Morgante, Francesca Bavikatte, Ganesh Anwar, Fahim Mohamed, Biju |
author_sort | Morgante, Francesca |
collection | PubMed |
description | Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson’s disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and their caregivers, the impact of which can be both physical and psychosocial. Treatments for sialorrhoea range from lifestyle and behavioural guidance, to medications, surgery or radiation. Nonpharmacological interventions include advice on posture, swallowing control, cough management, dietary changes, eating and drinking techniques, and behavioural modification; however, these conservative measures may be ineffective for people with progressive neurological conditions. The pharmacological treatment of sialorrhoea is challenging because medications licensed for this purpose are limited, but treatments can include anticholinergic drugs and botulinum toxins. Surgical treatment of sialorrhoea is typically reserved as a last resort for patients. IncobotulinumtoxinA (Xeomin®) is the first botulinum toxin type A to receive US and UK marketing authorization for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults. In this review, we discuss and compare the frequency and method of administration, location of treatment delivery, approximate annual costs and main side effects of botulinum toxin and different anticholinergic drugs. Management of patients with chronic neurological conditions requires input from multiple specialist teams and thus a multidisciplinary team (MDT) approach is considered fundamental to ensure that care is consistent and tailored to patients’ needs. To ensure that adult patients with neurological conditions receive the best care and sialorrhoea is well managed, we suggest a potential clinical care pathway for sialorrhoea with a MDT approach, which healthcare professionals could aspire to. |
format | Online Article Text |
id | pubmed-6883364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-68833642019-12-09 The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®) Morgante, Francesca Bavikatte, Ganesh Anwar, Fahim Mohamed, Biju Ther Adv Neurol Disord Supplement Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson’s disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and their caregivers, the impact of which can be both physical and psychosocial. Treatments for sialorrhoea range from lifestyle and behavioural guidance, to medications, surgery or radiation. Nonpharmacological interventions include advice on posture, swallowing control, cough management, dietary changes, eating and drinking techniques, and behavioural modification; however, these conservative measures may be ineffective for people with progressive neurological conditions. The pharmacological treatment of sialorrhoea is challenging because medications licensed for this purpose are limited, but treatments can include anticholinergic drugs and botulinum toxins. Surgical treatment of sialorrhoea is typically reserved as a last resort for patients. IncobotulinumtoxinA (Xeomin®) is the first botulinum toxin type A to receive US and UK marketing authorization for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults. In this review, we discuss and compare the frequency and method of administration, location of treatment delivery, approximate annual costs and main side effects of botulinum toxin and different anticholinergic drugs. Management of patients with chronic neurological conditions requires input from multiple specialist teams and thus a multidisciplinary team (MDT) approach is considered fundamental to ensure that care is consistent and tailored to patients’ needs. To ensure that adult patients with neurological conditions receive the best care and sialorrhoea is well managed, we suggest a potential clinical care pathway for sialorrhoea with a MDT approach, which healthcare professionals could aspire to. SAGE Publications 2019-11-28 /pmc/articles/PMC6883364/ /pubmed/31819763 http://dx.doi.org/10.1177/1756286419888601 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Supplement Morgante, Francesca Bavikatte, Ganesh Anwar, Fahim Mohamed, Biju The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®) |
title | The burden of sialorrhoea in chronic neurological conditions: current
treatment options and the role of incobotulinumtoxinA (Xeomin®) |
title_full | The burden of sialorrhoea in chronic neurological conditions: current
treatment options and the role of incobotulinumtoxinA (Xeomin®) |
title_fullStr | The burden of sialorrhoea in chronic neurological conditions: current
treatment options and the role of incobotulinumtoxinA (Xeomin®) |
title_full_unstemmed | The burden of sialorrhoea in chronic neurological conditions: current
treatment options and the role of incobotulinumtoxinA (Xeomin®) |
title_short | The burden of sialorrhoea in chronic neurological conditions: current
treatment options and the role of incobotulinumtoxinA (Xeomin®) |
title_sort | burden of sialorrhoea in chronic neurological conditions: current
treatment options and the role of incobotulinumtoxina (xeomin®) |
topic | Supplement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883364/ https://www.ncbi.nlm.nih.gov/pubmed/31819763 http://dx.doi.org/10.1177/1756286419888601 |
work_keys_str_mv | AT morgantefrancesca theburdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin AT bavikatteganesh theburdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin AT anwarfahim theburdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin AT mohamedbiju theburdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin AT morgantefrancesca burdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin AT bavikatteganesh burdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin AT anwarfahim burdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin AT mohamedbiju burdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin |